TREVOSE, Pa., Nov. 7, 2022 /PRNewswire/ -- Lannett Company, Inc. (LCI) today announced that it has entered into an agreement with Ypsomed AG, the manufacturer and supplier of the pen injector ...

Mylan also makes the distinction that this isn’t the Semglee brand pen, but unbranded Insulin Glargine-yfgn pens. This covers batch No. BF21002895, expiration August 2023.

Mylan Pharmaceuticals Inc., a Viatris company, is voluntarily recalling one batch of Insulin Glargine (Insulin glargine-yfgn) Injection, 100 units/mL (U-100), 3 mL prefilled pens which are ...

Mylan also makes the distinction that this isn’t the Semglee brand pen, but unbranded Insulin Glargine-yfgn pens. This covers batch No. BF21002895, expiration August 2023.

In addition, “the use of biosimilar insulin, which was first approved in 2015, increased from 2.6% in 2017 to 8.2% in 2020 of total insulin treatment visits,” while “the total number of ...

Patients were randomly assigned (1:1) to receive their insulin using pen devices or vials and syringes. The study was conducted in accordance with the Declaration of Helsinki. [16] ...

Lannett previously said that subject dosing has been completed in the pivotal clinical trial of Lannett/HEC's biosimilar insulin glargine and no serious adverse events were reported. The company ...